TENAX THERAPEUTICS INC
TENXNASDAQTrading Snapshot
- Day Range
- $1.83 β $1.85
- 52-Week Range
- $1.31 β $19.40
- Volume
- $1.72B
- Avg Volume
- $2.12B
- Shares Outstanding
- 26.5M
- Next Earnings
- Dec 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +156.8%
Why Investors Own TENX
- βHigh-growth profile β revenue up +32.9% YoY with expanding US Equity exposure.
- βHealthy economics β 49% gross margin and 6% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TENAX THERAPEUTICS INC
TENX
StockOtter Β· stockotter.spaceAbout TENAX THERAPEUTICS INC
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stock
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) Director Declan Doogan purchased 53,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an aver
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (βTenaxβ or βTenax Therapeuticsβ or the βCompanyβ) announced today that Chris Giordano, President & Chief Executive Officer, w
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 19, 2026
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)
Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is in
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (Γ’ΒΒSBSΓ’ΒΒ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv